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Factors that influence enrollment in syringe
services programs in rural areas: a qualitative
study among program clients in Appalachian
Kentucky
Umedjon Ibragimov1* , Katherine E. Cooper1, Evan Batty2, April M. Ballard1, Monica Fadanelli1, Skylar B. Gross1,
Emma M. Klein1, Scott Lockard3, April M. Young2 and Hannah L. F. Cooper1

Abstract
Background: Enrolling sufficient number of people who inject drugs (PWID) into syringe services programs (SSP) is
important to curtail outbreaks of drug-related harms. Still, little is known about barriers and facilitators to SSP enrollment in rural areas with no history of such programs. This study’s purpose was to develop a grounded theory of the
role of the risk environment and individual characteristics of PWID in shaping SSP enrollment in rural Kentucky.
Methods: We conducted one-on-one semi-structured interviews with 41 clients of 5 SSPs that were established
in rural counties in Appalachian Kentucky in 2017–2018. Interviews covered PWID needs, the process of becoming aware of SSPs, and barriers and facilitators to SSP enrollment. Applying constructivist grounded theory methods
and guided by the Intersectional Risk Environment Framework (IREF), we applied open, axial and selective coding to
develop the grounded theory.
Results: Stigma, a feature of IREF’s meso-level social domain, is the main factor hampering SSP enrollment. PWID hesitated to visit SSPs because of internalized stigma and because of anticipated stigma from police, friends, family and
healthcare providers. Fear of stigma was often mitigated or amplified by a constellation of meso-level environmental
factors related to healthcare (e.g., SSPs) and social (PWID networks) domains and by PWID’s individual characteristics.
SSPs mitigated stigma as a barrier to enrollment by providing low threshold services in a friendly atmosphere, and by
offering their clients program IDs to protect them from paraphernalia charges. SSP clients spread positive information
about the program within PWID networks and helped their hesitant peers to enroll by accompanying them to SSPs.
Individual characteristics, including child custody, employment or high social status, made certain PWID more susceptible to drug-related stigma and hence more likely to delay SSP enrollment.
Conclusions: Features of the social and healthcare environments operating at the meso-level, as well as PWID’s individual characteristics, appear to enhance or mitigate the effect of stigma as a barrier to SSP enrollment. SSPs opening
in locations with high stigma against PWID need to ensure low threshold and friendly services, protect their clients
from police and mobilize PWID networks to promote enrollment.
Keywords: Syringe services programs, People who inject drugs, Rural Appalachia, Stigma
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Introduction
Syringe services programs (SSPs) are a proven [1] and
highly cost-effective [2–5] intervention to reduce the
risk of HIV and hepatitis C virus (HCV) transmission
among people who inject drugs (PWID). Modeling
suggests that expanding SSPs as HIV prevention interventions in the United States (USA) would cost about
$25,000 per quality-adjusted life-year [QALY] gained,
significantly below $50,000 per QALY benchmark of
public health cost-effectiveness [6]. As for HCV prevention, SSPs may save about $364,000 per case averted
[4]. Cost-savings of expanding SSP in combination with
other evidence-based interventions may be particularly
high for rural areas that have high prevalence’s of HCV
and other drug-related harms [5].
Historically, SSPs have been scarce in the rural US
though. In 2013, only 30 SSPs operated in rural areas,
and their capacity and funding were lower than SSPs
located in urban areas [7]. However, in response to the
escalating epidemics of substance use disorder (SUD)
and injection drug use (IDU)-related harms, including HCV, the state of Kentucky established more than
70 SSPs in five years following the legalization of this
intervention in 2015 [8]. Almost half (n = 32) of these
programs were opened in rural counties that were identified as experiencing or at high risk for IDU-related
HIV and HCV outbreaks [9]. This unprecedented
expansion of SSPs made Kentucky a US leader in the
number of SSPs serving PWID in rural areas.
Despite rapid expansion, SSPs in rural areas may
face challenges with PWID enrollment, which may
hamper programs’ ability to address the epidemics of
bloodborne infections at the population level. Lancaster et al. found that only 49% of PWID sampled in
five Appalachian Kentucky counties had ever utilized
SSPs, although 80% of the study participants had been
recruited in three counties where SSPs were operating
[10]. Allen et al. reported that almost 30% of PWID in
a rural West Virginia County received sterile syringes
from sources other than SSP [11]. To prevent or curtail outbreaks, a high proportion of PWID need to
enroll and start using SSPs and other evidence-based
programs. Modeling suggests that substantive and
cost-effective reductions in HIV among PWID may be
achieved if at least half of PWID population regularly
receive SSP services [2]. Further, while SSPs may reach
PWID indirectly via satellite and secondary exchange,
in-person visits of PWID to SSPs are essential to link
them to a comprehensive range of services, including HIV and HCV testing and treatment, as well as
SUD treatment, wound care, housing and other social
services [12–16]. However, literature on factors that
may influence PWID enrollment into SSP services in
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high-stigma areas with no history of harm reduction
programs is limited.
In this regard, an important question in studying SSP
expansion in areas with no history of such programs is
assessing factors that may accelerate or slow down enrollment into this program. Stigma is one such formidable
barrier for PWID. It may take various forms, including
public stigma (defined as negative stereotypes and judgmental attitudes toward PWID), enacted stigma (defined
as overt ostracism and discrimination against PWID);
anticipated stigma (defined as avoiding situations such as
a visit to SSP that may disclose one’s drug use and expose
one to enacted stigma); internalized stigma (defined
as feelings of shame and unworthiness that affect one’s
behaviors); and structural stigma (e.g., repressive drug
policies and policing practices) [17–19]. Each of these
forms of stigma either directly prevents PWID from
engaging with SSPs and other health-related services, or
fuels other forms of stigma and discrimination [10, 18–
27]. Stigma may differentially impact sub-populations of
PWID—for example, women who inject drugs may be
subject to stronger stigma than men [28]. Stigma is an
important barrier to services in rural Appalachia: PWID
living in this region report that anticipated stigma is a
reason to avoid attending SSPs or obtaining and carrying
clean syringes [10, 20, 26]. Public stigma against PWID
and related local opposition to harm reduction hampered
access to drug-related services in the region, including
preventing new SSPs from opening or closure of existing
ones [21, 24, 25, 29–33].
Given the importance of enrolling a high proportion of
PWID into SSP in high-risk settings and limited knowledge on barriers and facilitators of SSP enrollment in
rural areas, we conducted a qualitative study among program clients in five rural counties in Appalachian Kentucky that had opened an SSP in 2017–2018. The study’s
purpose was to develop a grounded theory of the role of
the risk environment and individual characteristics in
SSP enrollment among PWID. Since IDU-related stigma
is prevalent in rural Kentucky, [10, 24, 29] we were especially interested in studying factors that may amplify or
mitigate the role of stigma as a barrier to enrollment. The
study findings may inform planning and implementation
of SSP in rural areas.
Theoretical framework

We explore this topic using grounded theory methods—
a method of systematic exploration of raw data to infer
major constructs and relationships among them to
develop a theory explaining the phenomena of interest.
While grounded theory originally prescribed the use of
abductive logic without relying on a priori theories, constructivist grounded theory accompanies abductive logic
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with sensitizing concepts. These sensitizing concepts
may include theories and frameworks from the literature to inform the development of the grounded theory
[34]. Following the advice by Charmaz on sensitizing
concepts, we used frameworks as “…points of departure
from which to study the data” [34 p. 259], not as defining premises of our grounded theory. This helped us to
align our analysis and grounded theory with the existing
literature on drug-related risks and services. Specifically,
Collins and colleagues’ Intersectional Risk Environment
Framework (IREF), [35] an extension of Rhodes’ Risk
Environment Framework (REF) informed our analyses. REF posits that drug-related risk behaviors, including service utilization, are the function of influence and
interaction of external forces mapped by REF into environment domains (physical, social, policy, economical,
law enforcement and healthcare) and levels (macro-,
micro-, and, in some literature, meso-level). REF posits
that stigma is a feature of macro-level social environment, rooted in negative stereotypes, norms and beliefs
prevailing in rural communities, and intertwined with
policy and law enforcement (“War on Drugs”) environments [29]. IREF extends REF by conceptualizing an
intersecting social location of an individual (a set of individual characteristics, such as age, gender, race, defined
by the systems of oppression or privilege) as a mechanism mediating and modifying the impact of risk environment on individual health outcomes [35].

Methods
Study design

We employed a qualitative multiple-case study design;
individual SSPs in each of the five study counties were
treated as separate cases [36]. To preserve anonymity
of the study participants, we do not mention the county
names. A case study design is suitable for studying realworld phenomenon (here, SSPs) in situations where the
boundaries between the phenomenon and the context
(PWID networks, service providers, communities) are
not clearly delineated. In multiple-case studies, each
case (SSP) is considered a replication of an “experiment”
generating data to develop and iteratively refine a theory
explaining the phenomenon [36–38]. Prior to conducting
interviews with SSP clients, we reviewed the interview
guides with SSP managers, staff and directors of health
districts overseeing local health departments in the study
counties.
Setting

The study gathered data from SSPs in five counties in
Appalachian Kentucky. These SSPs were managed by
county health departments and located within county
health centers; no mobile SSPs had been launched in
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these counties at the time of data collection. Service
provision was not uniform across the SSPs: some were
open during most business hours four or five days a
week, while others were open only a couple of hours
one or two days a week. Some SSPs had more strict
syringe exchange policies than others (e.g., at some
SSPs clients could exchange up to 200 syringes per visit,
while in others a cap was set at 20 or 40). All counties
were rural, ranking between 7 and 9 on USDA Rural–
Urban Continuum Code (1—most urban, 9—most
rural) and with population density ranging between
23 and 85 people per sq. mile [39, 40]. As elsewhere
in rural Appalachia, these counties struggle with high
levels of health disparities, poverty and unemployment
as the result of decline in coal mining and agriculture
[40–43]. As in many US rural areas, these counties were
geographically remote and residents were often isolated; public transportation was limited and healthcare
facilities operated under resource constraints [41, 42,
44, 45]. The opioid epidemic that hit the area hard has
been accompanied by a high prevalence of HCV, IDU,
overdoses and condomless sex [46–50]. Four of the five
study counties were determined by CDC to be experiencing or at high risk for HIV and HCV outbreaks due
to IDU, with three of the counties ranking among the
top 30 most vulnerable to such outbreaks [9]. Previous
studies reported dense and overlapping social and drug
use networks, often including members of the same
families, as a key characteristic of the risk environment
[51–53]. These dense social networks and intergenerational ties are the main feature of communal resilience,
defined as an ability of individuals, families and communities to harness their social support systems to
overcome or cope with multiple challenges of everyday
life in these impoverished and underserved rural areas
[51–53].
Sampling and recruitment

SSP clients were the population of interest for this
study. Eligibility criteria included being aged 18 or
older; receiving syringes at one of the five SSPs at least
three times in the past three months; and residing in
the county where SSP operated for at least six months.
SSP clients were recruited in three ways: (1) via SSP
staff, who referred interested clients to research assistants (RAs); (2) RAs approached SSP participants at
SSP premises; and (3) RAs contacted participants of the
parent study cohort who reported using SSP services at
the time of the survey and had agreed to be contacted
about future research. Our final sample comprised of
41 PWID—program clients. All participants provided
verbal informed consent.
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Data collection

We collected data via in-person one-on-one semi-structured interviews. The interview guide covered the following topics: injection practices prior to attending the
SSP and unmet needs; the processes of becoming aware
of SSPs in the county and making the decision to start
participating in it; and barriers and facilitators to the
first SSP visit. Interviews were audiotaped with participant consent. In addition, we conducted a mini-survey
to collect data on participants’ sociodemographic characteristics, drug use and SSP service utilization patterns.
Participants were offered $20 cash as a compensation for
their time. Interviews were conducted between December 2018 and January 2020 (all SSPs had been operating
for more than one year by the start of the interviews).
The study has been approved by Emory University Institutional Review Board (protocol IRB00107426).
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Table 1 Demographic characteristics, drug use practices and
length of SSP participation (N = 37)
Characteristic

n (%)*

Age (mean, SD)

37.6 (8.9)

Gender
Men

17 (45.9)

Women

20 (54.1)

Race/Ethnicity
White non-Hispanic

35 (94.6)

Other

1 (2.7)

Refused to answer

1 (2.7)

Commonly reported drugs used (past 3 months)
Methamphetamine

25 (67.6)

Marijuana

19 (51.3)

Prescription opioid painkillers

15 (40.5)

Prescription sedatives

15 (40.5)

Heroin

12 (32.4)

Gabapentin

12 (32.4)

Data analysis

Suboxone

11 (29.7)

A constructivist grounded theory approach was used
throughout the data collection and analysis phases [34].
Interview guides were iteratively reviewed and revised
based on the study findings and emerging grounded
theory. Interview records were transcribed verbatim and
coded in NVivo 12.0 software (QSR International).
We started with a within-case analysis, in which we
analyzed data from each county (there was one SSP in
each county), one at a time. The within-case analysis
had three stages—open, axial and selective coding—and
each stage employed constant contrast and comparison
techniques. We documented our analyses in memos for
each county. After reading each transcript multiple times
to immerse ourselves in the data, two coders started the
open coding process independently by labeling concepts
in four initial transcripts and developing the codebook.
Concepts with similar meaning or pertaining to the same
phenomena were combined into higher order categories. We revised the codebook iteratively as new codes
and categories emerged while coding the remaining
transcripts. Subsequently, every fourth transcript was
double-coded to enhance reliability; discrepancies were
resolved by having a third person code the discrepant
text and subsequent discussion in the team. At the axial
coding stage, we linked categories to each other by developing relational statements. During selective coding, we
selected the central category (here, “stigma as a barrier to
SSP”) most saliently related to our research question. We
consulted our theoretical framework (the Intersectional
Risk Environment Framework) when we labeled the
major categories of the theory. For example, we grouped
into IREF domains (e.g., policy, social, healthcare and law
enforcement) the external factors related to the central

Fentanyl or Carfentanyl

6 (16.2)

Cocaine

5 (13.5)

Commonly reported drugs injected (past 3 months)
Methamphetamine

24 (64.9)

Prescription opioid painkillers

16 (43.2)

Heroin

12 (32.4)

Suboxone

11 (29.7)

Fentanyl or similar
Cocaine
Number of months since first visit to the SSP (mean, SD)
*

5 (13.5)
3 (8.1)
13.2 (7.8)

% are calculated for participants who participated in the mini-survey (n = 37)

category. This three-stage process was repeated for each
county.
In the cross-case analysis stage, we refined the emerging grounded theory by comparing and contrasting major
categories and the relationships between them across the
counties (cases). Specifically, we looked for literal replications (similar findings) and theoretical replications
(contrasting findings predicted by the theory) of the core
categories and the relationships between them. This contrast and comparison process was recorded in the final
memo, which encompassed findings from all counties
and described the grounded theory reflecting differences
and similarities across the counties.

Results
The study participants—SSP clients

Mini-surveys were completed by 37 out of 41 participants (four participants did not complete the minisurvey; Table 1). Our full sample consisted of 18 men
and 23 women (according to the screening data). The
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Social domain

Policy domain
Law enforcement domain

Structural stigma
(drug paraphernalia laws,
child custody policies)

Community

Stigma enacted by
police

Public stigma (norms
and stereotypes)
Small, interconnected
communities

Healthcare domain
Non-SSP

Gender

Stigma enacted by
providers
High risk of bloodborne
infections

Job

Cost of non-SSP
syringes

Individual PWID

Parenting/
child custody

Anticipated
and
internalized
stigma

Family
status

Delaying 1st visit
to SSP

Enacted stigma
(families and friends)

PWID networks
Peers encouraging
SSP enrollment
SSP awareness and
reputation among
PWID networks

Need for
syringes

SSP
SSP core components
(low threshold
friendly services
meeting PWID needs)
Legend

Causal relationships based on the study data
Causal relationships based on literature
Amplifying or diminishing effect on stigma

Fig. 1 Model of syringe service program initiation by people who inject drugs (following the Intersectional Risk Environment Framework)

subsample that responded to the mini-survey included
17 women (45.9% [unless indicated otherwise, the
denominator for percentages in this paragraph is 37—
the number of the mini-survey participants]) and 20
men (54.1%), both young and middle-age adults, with
mean age of 38 years. Almost all participants self-identified as non-Hispanic white, consistent with the local
racial/ethnic composition. The most commonly used
drugs were methamphetamines (67.6%), marijuana
(51.3%), prescription opioids (40.5%) and prescription sedatives (40.5%). Methamphetamines were also
the most commonly injected drug in the three months
prior to the interview (64.9%), followed by prescription opioids (43.2%) and heroin (32.4%). On average,
participants started visiting study SSPs more than a
year before the interview time (mean = 13.2 months).
According to the individual interview data, about half
of our participants reported postponing their first visit
to SSP for a month or longer after first hearing about
the program, and several of them (7 out of 41) waited
for six months or longer.

Overview of the grounded theory

According to our grounded theory (Fig. 1), prior to visiting SSPs PWID were in high need of free sterile syringes
due to the high cost and limited access of syringes outside of SSPs. Still, PWID hesitated to visit SSPs because
of stigma. They feared persecution by law enforcement,
and judgment and ostracism by friends, family, healthcare providers and by the general public. We categorized
this fear as anticipated stigma. PWID also hesitated
to enroll in the SSPs because of shame and feelings of
unworthiness related to their drug use; we categorized
these experiences as internalized stigma. According to
our emergent grounded theory, anticipated and internalized stigmas were mitigated or amplified by individual(gender, child custody, social status), network- (family,
peer support) and organizational-level (low thresholdSSP services) factors.
We start illustrating the theory by describing two
cases—one participant who waited for a long time after
hearing about the SSP, and another who started visiting
the SSP soon after learning about the program. These

Ibragimov et al. Harm Reduct J

(2021) 18:68

Page 6 of 15

alcohol and bleach; she also reused her own syringes.
To the best of her knowledge, Nancy did not inject
with borrowed syringes before attending the local SSP
because she was concerned about her health. Nancy
had no prior awareness of SSPs and heard about the
program in her county via her social network: a close
friend who was an SSP client told her about the program. Internalized and anticipated stigma were the
main barriers delaying SSP enrollment. A long-time
resident in her small rural county, Nancy was ashamed
and embarrassed at the thought of potentially bumping into an acquaintance there:

cases provide real-life illustrations of how network,
organizational and individual-level factors influenced
our participants’ decision to start visiting SSP (Box 1).
Case descriptions are followed by detailed and structured descriptions of the findings elucidating the main
categories of the grounded theory and the relationships
between them.
Box 1. Deciding to visit SSP—short and long lag (delay
in the first visit to SSP)

Case # 1 (short lag): Todd (pseudonym) is 37 years
old, has young children and lives in county B. Prior to
enrolling in the SSP, Todd used to buy syringes from
pharmacies and on the black market. He reused his
own syringes after cleaning them, and did not practice
receptive syringe sharing. He learned about the program via his social network—a friend told him about
it. Unfamiliar with SSPs, he initially hesitated to visit
the program for about two weeks because of anticipation of structural stigma—he feared that police may
arrest him for drug possession or under some other
pretext. He was also worried about losing custody of
his children if SSP staff reported him to child protection service:

… this is a very small town. I’ve lived here my entire
life. Just the fact of running into [people I know] – I just
find it really embarrassing. I find it mortifying, really.
Nancy was also concerned about police seeing her
visiting the program. She discussed the possibility of
visiting the SSP with her friend and her boyfriend,
who encouraged her to enroll to the program. Eventually her need for syringes, both for herself and her
brothers, overcame her concerns about stigma, and
motivated her to enroll. One day, six months after first
hearing about the program, Nancy mustered the courage to visit the program unaccompanied. After enrolling in the SSP, Nancy encouraged her boyfriend to
start attending too.

I’m like oh man, … they’re going to arrest you when you
go up there [to SSP] … They’re going to get you for a PI
or public intoxication, I mean DUI or try to hit you
with possession or something. Because I had a nephew
get a county year in jail for having a syringe… And, so
I thought, no man, you know you all crazy to do it. […]
I thought maybe – I have kids, right, so I thought well,
I’ll come up [to SSP], I go up and sign my name…, [then
SSP staff ] want [to notify] social workers, you know
what I mean, with kids and whatnot.

I: Okay. So then what kind of led you to the decision to
come? You said it took you about six months, and you
were talking to your friend.
P: The fact of having clean syringes – that was a very
important thing. It was a lot safer that way.
I: So, who all did you talk about coming here with?
P: Well, she’s a really close friend of mine; and my boyfriend at the time – my boyfriend – we talked about
it. I came first. I just decided one day. I couldn’t make
myself come, actually; and then one day I decided to
try it, and I came without letting anybody know. I just
came hoping for the best, that there wouldn’t be a lot of
people. I didn’t know what to expect. I came, and then I
told [my boyfriend] about it; and then he started coming, too.

However, his social network members who had visited the SSP helped him overcome his concerns when
he talked to them and found out no one had been
arrested:
Interviewer (I): So, after you first heard about it, about
how long did it take you to decide and go to the program?
Participant (P): … about two weeks, first week I was a
little bit hesitant about it, … talked to somebody that’d
been here and went [to SSP]. And seen that they wasn’t
in jail, and I thought alright, I’ll go.
Case #2 (long lag): Nancy (pseudonym) is 41 years old,
a mother of two children (one of them young), has two
brothers who also inject drugs, and lives in county A.
Nancy hesitated for six months before deciding to visit
the program. Prior to SSP enrollment, she too used to
buy syringes on the black market, cleaning them with

Healthcare environment—scarcity of syringes
outside of SSP

Unmet need for free and sterile syringes1 was the main
reason that PWID started visiting SSPs. Lack of access to
syringes and their high cost outside of SSPs were main
features of healthcare environment that drove high need

1

Throughout the text we refer to syringes as a set of a syringe and needle.
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for sterile syringes among PWID. In the absence of sterile
syringes, PWID engaged in risky injecting practices.
Prior to visiting the SSP, PWID in all counties had
highly unreliable access to syringes because it was difficult to purchase them over the counter. Almost all participants prior to enrolling in the SSP bought syringes
on the black market from people who sell drugs or from
people with diabetes. Black market syringes cost about
$5 per syringe,q12 a price too high as mentioned by many
participants. In addition, syringes bought on the black
market might not be sterile:
P: You’d never know when you’d be able to get a new
[syringe] or not. Some people you’d have to watch
out, because they would try to sell you some; and
they’d be used. […] the new ones – they’ve got an air
pocket that you have to pop when they’re brand new.
[…] It’s not on the used one.

- a man from county A
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postponing their first visit to SSP after learning about
the program for a month or longer. All participants who
delayed their visit to the SSP and some participants who
started visiting the SSP relatively soon after hearing about
it expressed reluctance to visit the program because they
anticipated various forms of drug-related stigma. Here,
we describe the most common forms of stigma that
caused concern and delayed SSP visits: a) fear of persecution by law enforcement and other legal repercussions; b) anticipation of stigma enacted by public, family
and friends if their drug use were disclosed; and c) fear
of possible mistreatment by SSP providers. Importantly,
participants’ accounts also elucidated how individual and
environmental factors mitigated or amplified the fear of
stigma as a barrier to visiting SSP. We describe the various types of anticipated stigma and factors modifying its
effect in the subsections below.
Fear of law enforcement

Several participants mentioned buying syringes without a prescription in pharmacies located in large cities
outside of the study area. The cost of syringes in these
pharmacies was much lower—$13 per 100—compared
to the black m
 arketq2. However, PWID had to spend considerable time driving to large cities to buy syringes from
pharmacies, and urban pharmacies were not always a
reliable source of syringes since pharmacists might have
refused selling syringes at their discretion:

PWID feared that visiting an SSP would provide evidence
of illicit drug use, and so were reluctant to start visiting
SSPs. Many participants were afraid that the SSP was a
police setup to identify and target PWID. Some participants initially believed that SSP staff collaborated with
police and shared information about clients. One participant refused to visit the SSP when she heard about it,
since she believed police would arrest PWID visiting the
program.

But like back in the day when you used to be able
to buy them at Walmart…in Lexington. We had to
drive … to Lexington to get a dollar and a half pack
of rigs. […] But then we started coming and getting
too many and they shut us down.

- a woman from county E

They was a friend of mine that told me that this
program was going on; and I said, my God. I said
every one of us in this town is going to go to jail. […]
I thought it was just a joke really; and [my friend
is] like, no, they give [syringes], and then you take
them back every time you – I said you’ve lost your
mind, because when you go down there and do there,
there’s the law going to be sitting there, take your ass
to jail. I said well, when you go to jail, don’t say I
didn’t tell you so.

- a woman from county C

Limited access to syringes led to risky injection practices—almost all participants reported reusing their own
syringes and some participants reported engaging in
receptive syringe sharing (i.e., using a syringe after someone else) prior to SSP enrollment. Reusing old syringes
made the needles dull and burred, resulting in injured
and scarred veins and soft tissue, also causing pain and
discomfort. A man from county B described using a dull
needle as “…sticking a railroad spike in my arm.”
Stigma and hesitation to visit SSP

As shown above, many participants in our sample
had unmet demand for sterile inexpensive syringes.
Nevertheless, about half of our participants reported

2

Here and below we use numbered superscripts to reference additional
quotes compiled in the Additional file 1.

This fear of police was based on past persecution of
PWID by law enforcement, as reported by many participants. While most participants’ accounts of stigma
enacted by law enforcement focused on police officers
stopping, searching, arresting and confiscating syringes
from SSP clients, some participants also recalled episodes
of arrests and imprisonment for paraphernalia charges
that occurred prior to the SSP’s opening. Persecution
of PWID by police was not a mere act of enforcing the
law, but also manifestation of stigma against PWID since
many police officials shared negative attitudes toward
PWID. A participant recalled the local sheriff ’s political
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platform based on “cleaning up” the county by incarcerating people who use drugs:
P: Well, during his campaign he kept hollering that
he was going to “clean up” [our] County, he was going
to put all the drug addicts in jail, he was going to put
all the drug dealers in jail, and he just looks down on
us. That we’re nothing, more or less...

- a woman from county C

Fear of public stigma

Anticipation of public stigma was a common reason for
delaying SSP enrollment. PWID feared that their family members, friends, employers and other members of
the general public would find out about their drug use
if they visited SSP. According to participants, public
stigma toward PWID was prevalent in the study counties. PWID were perceived as people of lower value who
“do not matter,” who engaged in crime and damaged
the local communities.q3 In this setting, PWID wanted
to hide their drug use, even from their family members
and friends. They worried that visiting the SSP might
inadvertently reveal their drug use and subject them to
ostracism and ridicule by kin and kith. Some participants
mentioned visiting SSPs in another county to avoid being
seen by familiar people. In some cases, PWID concealed
their drug use from family members to spare them from
embarrassment and stigma by association. A participant
mentioned that while her adult children might know
she used drugs, she did not want them to be confronted
about it by others:
[…] like I said, my children were of age, I didn’t want
them to find out [about my drug use]. In the same
talking, my daughter’s a social worker she probably knows more than I think she knows. She’ll be
a [healthcare professional] coming this spring when
she graduates this year… So, she probably knows a
whole lot more than what I think. But I just didn’t
want them exposed to that. And I didn’t want them
to have people coming up and say, hey, we’ve seen
your mom with at the needle exchange. So that’s the
only [concern I had about visiting SSP].

- a woman from county B
Living in small tight-knit communities where many
people know one another and rumors spread fast amplified fear of public stigma. In some cases, PWID were
reluctant to visit the SSP since their friends or acquaintances worked at county health centers where SSPs were
located. PWID feared that these people might tell their
families and friends about their SSP use:
Some people don’t want nobody seeing you come in
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to get [syringes], some people’s parents or kinfolks
work [in the Health Center], or lives next to a person
that lives here and they don’t want them to know.

- a man from county C
Anticipation of public stigma was seemingly compounded by internalized stigma, as some PWID avoided
SSPs because it reminded them of their perceived failure
and moral weakness.q4, q5 A participant was embarrassed
to visit SSP because she was ashamed of her drug use:
I: Were you worried about anything about trying this
program out for the first time?
P: Just ashamed and didn’t want no one to know me,
which no none here knows me much anyway, but that’s
not the point. I just - there’s always going to be shame.
I’m 48 years old. I’m a grandma. I didn’t get it over
this to kick it in the butt - kick it to the curb, you know.
And I’m trying my best to do so. The day I don’t have
to come here and get a pack of needles I’ll be so happy.

- a woman from county D
PWID might also delay visiting SSPs due to anticipation
of stigma by SSP staff. As indicated above, living in a small
community increased chances of PWID seeing someone
familiar working at a SSP or health center. Some participants believed that SSP staff would share clients’ information with law enforcement or treat clients with prejudice.q6
Fear of stigma by SSP staff might be based on negative experiences of PWID who were stigmatized by other healthcare
providers. A participant recalled a disparaging remark from
a local clinic staff:
[Healthcare staff] treat you like you’re nothing. Like
you’re trash. … You look a certain way, whether you’re
a user or not, you’re being treated as one. This area is
real bad for it. I know when I had MRSA, I had a problem with one of the staff [who] made a comment to me
that, "You’re nothing more than an old dopehead drug
user, and I don’t even know why we’re fooling with you."

- a woman from county D
Distrusting healthcare systems, some participants simply
did not find the idea of an SSP credible initially. One of the
participants who delayed joining SSP did so due to his disbelief in the idea of SSP:
I: What did you think about the program when you
first heard about it? Or how did you feel about the program?
P: I was sketchy about it at first, until I started actually going…. I just thought it was too good to be true or
something. I don’t know. If something sounds good, it’s
usually not a good thing, you know?

- a man from county A
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Factors modifying stigma as a barrier to first visit

While analyzing stigma as a reason for the first visit to
SSP, we identified several categories that amplified or
mitigated the level of anticipated stigma or helped the
participants to overcome strong anticipated stigma.
These factors, including individual characteristics as
well as factors belonging to social (PWID networks) and
healthcare (SSPs) domains, are discussed below.
Individual‑level factors modifying anticipated stigma

The data suggest that gender is an important individual-level factor modifying the effect of stigma on delaying the first visit to the program. Notably, participants’
gender may both amplify and mitigate stigma as a barrier. SSPs were located in county health centers, and several participants mentioned that they knew it as a place
where women, including women with children, were
regular visitors. Some women appeared to be more comfortable visiting these SSPs than men, as they found it
easier to conceal their visit to an SSP as a visit for other
purposesq7:
I: What concerns did you have about coming to the
program?
P: I didn’t have any. I just don’t want people to know
what I do. I make up a story about something else
that I do [in the county health center], but I just
don’t want anybody to know.
I: Do you mean you tell them you’re at the health
department for something else?
P: Yeah.

- a woman from county C
The role of gender was complex, however, and data
also suggest that women, in particular mothers, might be
more vulnerable to stigma, because society expects them
to care for children and drug use was seen as not compatible with motherhood:
I: Do you think there are any particular kinds of people like women or younger people who might be less
likely to come to the program?
P: Yes, mothers, young mothers or mothers in general, who just don’t want people to look down upon
them because they’re a mother or look down upon
their kids somehow you know what I’m saying. They
just don’t want people to think bad of them, like, I
don’t have [to be seen as] a bad mom because I use.

- a man from county E
PWID with young children were also susceptible
to structural stigma, since disclosure of drug use status might jeopardize their child custody.q8, q9 Notably,
not only women, but also several men in our sample
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expressed concerns about losing child custody or exposing children to stigma by association:
P: My kid ain’t never seen nothing, she never see
nothing. I don’t even [use drugs] when I’m at the
house. I always do it when I’m gone.
I: Where you worried that your daughter would
know that you came [to SSP]?
P: Well, just maybe, maybe grown people would
get the information [about my drug use], you know
what I’m saying. Maybe cause me some problems …
Maybe [they will] call social [child protection] services or something … You got to worry about stuff
like that, especially round this town.

– a man from county B
Disclosure of drug use status might result in loss of
social status or damage to personal relationships of
PWID. Higher social status (including having higher
income, being employed, older age or high status in
family hierarchy) thus is a factor increasing individual’s
susceptibility to higher internalized stigma and fear of
anticipated sigma. Participants mentioned that some categories of professionals whose careers depended on their
reputation might be at higher risk of losing their job if
someone saw them at SSP:
A lot of people with, you know, jobs – like certain
kind of jobs don’t come to the program because, you
know, if the wrong person’s seen them at the program, then they’re more likely to get fired…
I: What kinds of jobs would you say?
P: Like [a registered nurse]. Say like any kind of public official definitely ain’t going to come in. Just professions like that. I mean, they’re – that’s for sure not
going to happen, you know.

– a man from county B
Social domain—network‑level factors modifying anticipated
stigma

While PWID might hesitate to visit SSPs lest their social
network members learned about their drug use, as shown
above, PWID networks also facilitated SSP enrollment
by advertising SSP services and addressing misconceptions about the program. Members of PWID social and
drug using networks played a significant role in reducing anticipated stigma among their peers and encouraging enrollment to SSP. Learning about the SSP from
people they knew was a reassurance for PWID who were
hesitant, especially if the person sharing the information
about the SSP has previously attended the program.q10,
q11
Many participants in our sample were accompanied
during their first visit by their family members, partners or other trusted peers who already started visiting
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the program.q12 Some PWID hesitant to visit SSP asked
their peers or non-PWID friends or family members to
visit SSP to check if it is a safe and legitimate service. This
happened particularly often when SSPs had just opened
and their reputation among PWID had not been established yet:
I said you go on and sign up for me and get your little things. What you want to do, you go over there
and get and I said, let’s see if you make it back down
here or not. I thought it was just a joke really […] I
sat down there [near SSP] and never moved from it.

- a woman from county C
Gradually, SSPs’ reputation of safe and legitimate services grew among PWID networks over time, as more
PWID spread positive information about the programs.
This was self-perpetuating: many participants also mentioned that after they started visiting SSP, they encouraged their friends to come to the program. Some of them
gave out new syringes from SSP to reassure their hesitant
peers:
I: So, since you’ve started coming here, have you
encouraged other people to come?
P: Oh yeah, word of mouth is the best thing you’ve
got.
I: What do you usually tell them?
P: Tell them that -- you know, I’ll give them a couple
[of new syringes] and switch them if they’ve got some
old ones and stuff. Look, just walk down the street.
They aren’t going to bite you, they won’t hit you, you
know, I’ve been in [SSP]. They aren’t going to arrest
you. So why not? You haven’t got nothing to lose
really.

- a man from county E
Healthcare domain—SSPs countering anticipated
stigma The provision of low threshold, anonymous
and PWID-friendly services by SSPs was a key for their
positive reputation among PWID, eventually helping to
assuage their fears and concerns related to visiting SSP.
All SSPs in our study took precautions to protect clients’
privacy and confidentiality, lest stigma prevents them
from enrolling to the program.q13 For example, SSPs’ location in county health centers allowed their clients to blend
in with other health center patients. Importantly, all SSPs
issued program IDs to their clients to protect them from
arrest or from police confiscation of their syringes. This
was a key motivation for many PWID to start attending
an SSP:
I: So then what kind of things would you say to these
people to kind of talk them into maybe giving [SSP]
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a try?
P: I’m thinking I ended up convincing like maybe one
or two. The card they give you, you know, showing
that you’re part of the program. So, if you get pulled
over by the cops and stuff, as long as you don’t have,
you know, the paraphernalia associated with it, you
know, you can, you know, skate by with it. You know,
that card was beneficial so they knew that if they
got caught with rigs in the car, you know, traveling
back home or something, you know, they’re good.
You know, they don’t have to worry about nothing. I
think that was the key to, you know, getting a couple
of my friends to start coming here.

– a man from county A
Personal awareness of or experience with SSPs also
helped participants to avoid or overcome hesitation to
visit the program. Participants who were aware of SSPs
prior to their first visit, especially those who visited SSPs
in other locations, knew about the program purpose
and confidentiality protection measures. These participants anticipated much less stigma and tended to visit
SSPs sooner.q14 We found no evidence that variations in
SSP operations (e.g., hours) were related to variations in
enrollment across programs.
Negative cases

Contrary to the numerous accounts of anticipated and
internalized stigma, there were several participants who
did not internalize stigma related to drug use (negative
cases). Across the study counties, several participants
were not worried about others finding out about their
drug use and visited a SSP soon after learning about it.
I: So, did you have any concerns about trying the
program out? Anything that made you a little bit
hesitant about coming?
P: No. At least get it over with, put this on that. I
said I don’t give a damn who knows it. You can put
it in the paper for all I care. That’s just the way I am.

- a woman from county D

Discussion
To effectively address epidemics of drug-related
harms, SSPs opening in areas such as rural Kentucky
with limited access to sterile syringes and high prevalence of IDU and HCV need to reach a high proportion of PWID. Drawing on empirical data and IREF,
we developed a grounded theory conceptualizing how
the interplay of PWID social locations (individual-level
characteristics) and various domains of the rural intersectional risk environment produces and influences
stigma as a major barrier to SSP initiation. The role of
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stigma as a barrier to SSPs and other services targeting PWID in the USA, including rural Appalachia, is
well documented [10, 17, 27, 54]. For example, 19% of
PWID surveyed in Appalachian Kentucky cited fear of
stigma as a barrier to SSP enrollment [10]. The most
prominent manifestation of anticipated stigma in our
study was fear of police persecution, a theme recurring in other publications on rural Appalachia [20, 55].
Enforcement of laws criminalizing possession of drugs
and injecting equipment is a well-documented structural determinant of health. Past research in Appalachia and elsewhere has found that PWID who fear
arrest tend to avoid SSPs and other HIV prevention
services, or are reluctant to carry injecting equipment
[20, 22–24]. Furthermore, fear of arrest, having been
arrested, police confiscation of syringes, not carrying or
buying syringes and rushing injections for fear of police
are linked to higher rates of HIV [22, 23].
Our findings corroborate this literature, showing how
various manifestations of stigma—anticipated, internalized, enacted and structural—make PWID reluctant to
visit SSPs despite high unmet need for sterile injection
equipment. The most important and novel contribution
of our grounded theory to the stigma literature, though,
is conceptualization of meso-level risk environment
domains and individual’s social locations as factors that
amplify or mitigate the role of stigma as a barrier to SSP
services in rural settings.
Our grounded theory suggests that social networks are
significant features of PWID’s meso-level social domain,
influencing the impact of stigma as a barrier to SSP services. Dense family and broader social networks, a mainstay of rural Appalachians’ social support system [52, 53,
56], may play both negative and positive roles in promoting enrollment in SSPs. Fearing loss of this support system, PWID may decide against visiting the SSP, since it
is hard to keep these visits private in small and tight-knit
rural communities, and because SSP are run by county
health center staff (the latter resulting from restricting SSP legislation in Kentucky, as discussed below).
On the other hand, PWID’s peer networks may mitigate
anticipated stigma by encouraging PWID to start visiting
SSPs. In rural areas, PWID networks are also indispensable in informing their peers about the programs, since
lack of awareness about SSP is one of the major barriers
to enrollment [10]. The positive role of PWID peer networks in promoting SSP use is documented in the literature, including a study among PWID in rural Kentucky
[26]. Globally, SSPs often capitalize on PWID networks
by actively involving PWID in service provision, including outreach work and secondary exchange [57, 58].
Importantly, IDU social network members may encourage PWID to visit SSP if only these services are worth
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visiting. This analysis found that the positive reputation
of SSPs among PWID networks was built and maintained by evidence-based implementation of services by
staff at the local SSPs (meso-level healthcare domain).
As attested by our participants, SSPs operating in these
counties attracted PWID by meeting their needs in a low
threshold, confidential and friendly manner. Specifically,
the programs offered free syringes and other injecting
equipment (both directly and via secondary exchange),
provided services anonymously, protected clients’ privacy
and treated them with dignity. SSPs also help to reduce
the impact of structural stigma by issuing program IDs to
protect their clients from police searches, syringe confiscation and arrest. These findings on the role of programs
and social networks in reducing stigma and promoting
access to services contribute to the growing acknowledgement of meso-level in REF literature, [59] showing
how these factors absorb the impact of negative forces
such as stigma acting at other levels of environment.
Notably, we found no evidence of a relationship
between SSP characteristics and enrollment delays.
Characteristics of SSP service provision mentioned in
the literature [26, 60], (e.g., hours of operation, syringe
exchange rules, lack of mobile SSPs or range of available
services other than sterile syringes) did not seem to factor into our participants’ decision to enroll to the SSP.
Perhaps these characteristics were not as important for
the first visit to the program as they might be for continuous SSP attendance, or for other program outcomes such
as client satisfaction or meeting their needs in services.
Similarly, our analysis did not identify factors pertaining to other domains of the rural risk environment that
might have affected delayed enrollment. For example,
geographic remoteness, lack of public transportation and
costly private transportation for impoverished residents
are well-known impediments to accessing drug-related
and other health care services in rural Appalachia, but
were not mentioned here [24, 55, 61–64]. Most likely,
these prominent features of the rural risk environment
may affect continuous attendance of SSP rather than
PWID’s decision to visit the program for the first time.
Our interviews did not elicit much information on
the impact of legal environment on SSP enrollment.
The state of Kentucky does not fully exempt SSP participants from drug paraphernalia charges, [65] which may
raise additional concerns among PWID contemplating
SSP enrollment. Kentucky’s SSP legal framework limits
syringe distribution to health departments and requires
approval of the new programs by local authorities, effectively preventing SSP establishment or limiting its scope
of operations in counties where municipal bodies disapprove of SSPs [66]. This legislation also prohibits community-based organizations (CBOs) from operating SSPs,
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which may create additional barriers for engaging PWID.
PWID, however, did not raise concerns relating to these
issues. We did identify though several individual-level
factors or, following IREF terminology, social locations,
that may interact with stigma as a barrier to SSP initiation. Gender is one such characteristic. While our sample
had roughly the same number of men and women as parents or custodians of underage children, women in the
USA are more likely to have custody over children than
men, [67, 68] and, in case of women who inject drugs, to
have child custody-related concerns about visiting SSP.
Literature also shows that women who inject drugs, in
particular mothers, are subject to harsher judgment by
the society as compared to men, and may be more likely
to avoid visiting harm reduction services [69]. Importantly, the aforementioned survey among PWID in Appalachian Kentucky found that men were more favorable
toward SSPs being located in county health centers than
women were, while women were more likely to prefer
local health department staff as SSP service providers
[10]. These findings suggest that while women are warier
to visit services in publicly visible locations, they prefer
service providers associated with serving women and
children.
High social location, including employment or position in a family hierarchy, may have shaped delays in
first visits: people who were higher status may have
been reluctant to attend the SSPs because of status loss,
a component of stigma. As conceptualized by Link and
Phelan, status loss, or “downward placement of a person
in a status hierarchy” [70 p.371], becomes a source of discrimination. Individuals with higher position in the social
hierarchy may also fear not meeting societal expectations
affixed to their status [71]. Consequently, for people of
higher status disclosure of their participation in stigmatized services is associated with failing societal expectations and facing discrimination.
Strengths and limitations of our study can be analyzed
via the prism of Maxwell’s [72] validity framework. We
enhanced descriptive validity (i.e., accurately capturing
the content of participants’ accounts) by audio-recording
the interviews and transcribing them verbatim. Interpretative validity (i.e., accurately conveying the meaning of participants’ accounts) was strengthened by joint
development of codebook and reconciliation of coding
discrepancies by the study team members. The steps
to improve theoretical validity (i.e., the extent to which
the grounded theory accurately reflects the phenomena of interest and the relationships between them)
included having a relatively large and diverse sample of
SSP clients; consulting theoretical frameworks widely
used in research on PWID; refining grounded theory
against findings across five counties (cases). However, the
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theoretical validity of our study may be undermined by
not including PWID who never visited SSPs. Overall, our
grounded theory has limited applicability to SSP in urban
settings due to lower anti-PWID stigma and higher level
of SSP clients’ anonymity (or lower public visibility) in
urban areas.
Public health and research implications

As suggested by our grounded theory and related literature, the impact of stigma on expanding SSP enrollment
and coverage may be reduced at meso-level by following
best practices of SSP implementation, including those
implemented by SSPs in our study. Based on our findings
and global literature on SSP, we suggest a range of recommendations for rural SSPs in Kentucky and beyond. As
demonstrated by SSPs in our study, anticipated stigma by
law enforcement may be addressed by program management and staff early by engaging local law enforcement
to protect the program participants from paraphernalia
charges and other forms of police harassment. Specific
protective measures include issuing program IDs, reducing patrolling of the areas surrounding SSPs, and anonymous service provision. Law enforcement officers may be
sensitized to the needs of PWID and importance of harm
reduction approaches, as demonstrated by available evidence-based anti-stigma interventions [73].
Early involvement of PWID as opinion leaders and
program ambassadors to spread news about SSP may be
particularly effective in rural settings with dense social
networks, because PWID in these areas tend to trust
their friends and family members more than healthcare
providers, and news is most efficiently spread via word of
mouth. Institutionalizing the role of PWID in SSP service
provision, such as formally enlisting them as volunteers
or hiring them as paid workers, as well as removing policies prohibiting SSP implementation by local CBOs and
grass-root groups representing PWID, may also help
convince hesitant PWID to enroll to the program.
Friendly and non-judgmental treatment of PWID,
low threshold enrollment practices (e.g., no requirements for picture ID, insurance, residency proof,
mandatory HIV testing, etc.) and maintaining clients’
confidentiality will further boost the program’s reputation among PWID networks that can catalyze enrollment, as shown by our study and elsewhere [74–76].
Further, the programs should prioritize coverage of
PWID with children and other individuals highly susceptible to stigma and legal repercussions, perhaps by
increasing awareness of SSP confidentiality protections
and expanding secondary syringe exchange. Multimodal service provision, including satellite and secondary syringe exchange, pharmacy-based and mobile
SSPs, and novel syringe sources such as syringe vending
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machines, may help programs to reach PWID at various stages of readiness to visit the program [10, 57,
58, 77, 78]. These meso-level interventions need to be
accompanied by macro-level reforms addressing structural stigma against PWID as captured by us and other
studies in rural Appalachia [10, 20, 55]. These reforms
should include decriminalization of drug possession
and injecting equipment possession, removing any burdensome and unjustified requirements for establishing
and operating SSPs and mandating non-prescription
sales of syringes at pharmacies. More research is
needed on how these meso- and macro-level changes
affect the enrollment of PWID into rural SSPs as well as
on other SSP implementation and program outcomes,
such as continuous attendance, reaching all PWID who
need SSP services and meeting their needs in services.
Conclusions

As rural counties in Kentucky expanded SSP services
at an unprecedented rate, little was known about how
stigma could affect the pace of PWID enrollment into
the programs in rural areas with no prior history of SSP
operation. We found, however, that the relationship of
stigma to enrollment appeared to vary by features of
the social and healthcare environments (e.g., PWUD
networks, organization of SSP services) and individual
characteristics of PWID (e.g., gender, child custody
and social status). SSPs opening in locations with high
stigma against PWID need to ensure low threshold and
friendly service provision, protect their clients from
police and mobilize PWID networks to promote rapid
enrollment. Broader legal and policy reforms may be
needed to lower barriers for SSP enrollment.
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